Where does G1 Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), G1 Therapeutics, Inc. ranks #7,555 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does G1 Therapeutics, Inc. hold?

G1 Therapeutics, Inc. holds 43 US utility patents granted between 2015 and 2024, spanning 5 technology areas.

What is G1 Therapeutics, Inc.'s Innovation Score?

G1 Therapeutics, Inc. has an Innovation Score of 37.7 out of 100 (top 43% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does G1 Therapeutics, Inc. focus on?

G1 Therapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 35 patents, ranking #241 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is G1 Therapeutics, Inc.'s patent grant rate increasing or decreasing?

G1 Therapeutics, Inc.'s recent grant velocity is +26% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for G1 Therapeutics, Inc.'s patents?

G1 Therapeutics, Inc.'s patents average 20.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the G1 Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

G1 Therapeutics, Inc.

USPTO PatentsView assignee record - 43 granted patents across 5 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, G1 ranks #7,555 of 49,997 tracked US assignees by granted-patent volume, with 43 patents across 5 technology areas.

#7,555
of 49,997 US assignees by volume: Top 43%
by Innovation Score (37.7/100): 20.8
avg claims per patent: +26%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R7555 · US Corporation #7,555 · 43 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 43 grants
UPPER-Q #7,555/49,997
PHOTO-FINISH Elektrobit Automotive
CPC-NARROW C07D · 5 areas
INNOV-THIN 37.7/100
CLAIMS-DENSE 20.8 claims/avg
TYPE-USCORP US Corporation
VEL-UP +26% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Elektrobit Automotive GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How G1’s 37.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.1 pts (35%) Velocity 4.2 pts (11%) Breadth 7.9 pts (21%) Claim depth 12.5 pts (33%)

Qualcomm Incorporated · highest

85
Everlight · near

38
G1 Therapeutics · this assignee

38
ResMed R&D Germany · near

38
Roxtec AB · near

38
Sync-rx · near

38
3D Lighting… · lowest

7

What this shows G1's Innovation Score is 37.7/100 (top 43% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for G1?

Each dot is one of G1’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). G1’s own 20.8 claims/patent is ABOVE the 14.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

G1 vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where G1's grants concentrate

G1 Therapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 81.4% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (7 grants) versus a trough of 1 in 2015. By volume, G1 sits between Elektrobit Automotive GmbH and GeeLux Holdings, Ltd..

G1's three-year grant acceleration

G1 Therapeutics, Inc. shows 12 grants in 2022–2024 against only 19 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Elektrobit Automo…

43
Evernorth Strateg…

43
Focal Point

43
Forsight Vision4

43
Getrag Getriebe-…

43
Gowin Semiconduct…

43
Granbio Intellect…

43
Geelux Holdings

43
G1 Therapeutics ◀

43

What this shows G1 holds 43 patents at rank #7,555, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near G1

By rank, the assignees closest to #7,555 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in G1's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for G1, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), G1 ranks #241 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (38 here).

Roxtec AB 38 Everlight Electronics Co., Ltd. 38 Sync-rx Ltd. 38 ResMed R&D Germany GmbH 38

G1's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 43% higher than 57% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

G1 Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	2.3%
2016	5	11.6%
2017	3	7.0%
2018	3	7.0%
2019	7	16.3%
2020	6	14.0%
2021	6	14.0%
2022	5	11.6%
2023	5	11.6%
2024	2	4.7%

Which technologies does G1 Therapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 35

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 34

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 27

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

C07C - Acyclic OR Carbocyclic Compounds 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

G1 Therapeutics, Inc.'s patent record in context - here's where to go next.

G1 Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 81.4% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #7,555 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare G1 Therapeutics, Inc. against Elektrobit Automotive GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.